Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Catalyst Pharmaceuticals excels in 2022, eyes sustained growth in epilepsy market

Catalyst Pharmaceuticals delivered exceptional financial performance in 2022, with strong revenue growth and strategic acquisitions positioning the company for continued success.
While facing challenges in maintaining sequential quarterly revenue growth, Catalyst's focus on innovation, patient care, and financial stability presents opportunities for sustained growth.
Overall, Catalyst's industry leadership, financial strength, and commitment to expanding product access and market presence underscore its potential for future growth and success.

Catalyst Pharmaceuticals reports record Q1 earnings, eyes growth opportunities

Catalyst Pharmaceuticals delivered exceptional financial results in Q1 2023, with strong revenue growth and a healthy cash position, positioning the company for continued success.
While facing challenges such as seasonal sales trends and diagnosis rates, the company's strategic focus on acquisitions and market expansion presents promising opportunities for future growth.
With a clear commitment to organic growth, product integration, and market penetration, Catalyst Pharmaceuticals remains poised for sustained performance and market leadership.

Catalyst Pharmaceuticals excels in Q2, eyes global expansion and new treatments

Catalyst Pharmaceuticals delivered strong financial performance in Q2 2023, driven by revenue growth and strategic initiatives.
While facing challenges in patient identification and treatment, the company remains focused on expansion and innovation in rare disease therapeutics.
Opportunities lie in upcoming product launches, global expansion, and collaboration efforts to drive future growth and market penetration.

Catalyst Pharmaceuticals (CPRX) excels in Q3, eyes global expansion

Catalyst Pharmaceuticals (CPRX) demonstrated robust financial performance in Q3 2023, driven by strong product revenues and strategic initiatives.
While facing challenges in managing launch expenses and regulatory processes, CPRX remains focused on leveraging growth opportunities through global expansion and portfolio enhancements.
With a new CEO appointment and a clear focus on market expansion and innovation, CPRX is poised for sustained growth and value creation in the pharmaceutical sector.

Catalyst Pharmaceuticals posts record revenues, eyes growth in rare diseases

Catalyst Pharmaceuticals delivered strong financial performance in 2023, driven by record revenues and strategic acquisitions.
While facing challenges with FYCOMPA's growth and upcoming patent expiry, the company remains well-positioned for growth in rare disease markets.
Opportunities lie in the launch of AGAMREE, expansion into new therapeutic areas, and leveraging the stickiness of epilepsy drugs post-patent expiry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

-The allowed claims are directed to methods of treating patients with a 3,4-DAP sensitive disease comprising administering 3,4-DAP or a salt thereof to slow acetylating patients having certain mutations in each allele of the NAT2 gene -The allowed claims are directed to methods of treating patients with a 3,4-DAP sensitive disease comprising administering 3,4-DAP or a salt thereof to slow acetylating patients having certain mutations in each allele of the NAT2 gene

Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for "Methods of Administering 3,4-Diaminopyridine"

Catalyst (CPRX) delivered earnings and revenue surprises of 12.50% and 2.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates

- Firdapse® Second Quarter Net Revenues of $29.6 Million

Catalyst Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update

Catalyst Pharmaceuticals (NASDAQ: CPRX) announces its next round of earnings this Monday, August 10.

Earnings Preview: Catalyst Pharmaceuticals

CORAL GABLES, Fla., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that Canada’s national healthcare regulatory agency, Health Canada, has approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with Lambert-Eaton myasthenic syndrome (LEMS), an ultra-rare, debilitating and potentially life-threatening neurodegenerative condition.

Catalyst Pharmaceuticals’ Firdapse® (amifampridine phosphate) Receives Marketing Approval in Canada for Patients with LEMS

CORAL GABLES, Fla., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced a change in the format of its 2020 Annual Meeting of Stockholders (the "Annual Meeting") from an in-person meeting to a virtual-only meeting format. The change is being made as a result of the coronavirus outbreak (COVID-19) and in order to protect the health and safety of Catalyst's stockholders and employees. There will be no in-person meeting. As previously announced, the Annual Meeting will be held on Thursday, August 20, 2020 at 9:00 a.m. eastern time.

Catalyst Pharmaceuticals Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of Stockholders

CORAL GABLES, Fla., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release second quarter 2020 financial results after market close on Monday, August 10, 2020. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Tuesday, August 11, 2020 to discuss the financial results and to provide a corporate update.

Catalyst Pharmaceuticals to Hold Second Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 11th, 2020

CORAL GABLES, Fla., July  31, 2020  (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the Magistrate Judge considering Catalyst's lawsuit against the FDA has filed a Report and Recommendation in which she recommends to the District Judge handling the case that she grant the FDA's and Jacobus' motions for summary judgement and deny Catalyst's motion for summary judgement. Catalyst is currently reviewing the Magistrate Judge's decision, which it believes to be incorrect as a matter of law, and intends to pursue the case further with the District Judge. The decision on whether to grant or deny Catalyst's motion for summary judgement remains with the District Judge handling the case.

Catalyst Pharmaceuticals Comments on Magistrate Judge's Report and Recommendation in its Lawsuit against the FDA

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Catalyst Pharmaceutical (CPRX) Q2 Earnings Expected to Decline

New York, New York--(Newsfile Corp. - July 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Catalyst Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Catalyst Pharmaceuticals, Inc. - CPRX

Green Brick Partners

MarineMax

As the market continues to grapple with the effects of the coronavirus pandemic, some investors are seeing strength among U.S.

3 US Small-Cap Stocks to Consider for Market Recovery

-Pete Curry has been Promoted to Vice President of Sales

Catalyst Pharmaceuticals Appoints Jeffrey Del Carmen as Chief Commercial Officer

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Catalyst (CPRX) Down 0.4% Since Last Earnings Report: Can It Rebound?

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q1 2020 Results - Earnings Call Transcript

Several catalysts could drive this biopharma higher, but there are some significant risks ahead, too.

Is Catalyst Pharmaceuticals a Buy?

Catalyst (CPRX) Up 52.1% Since Last Earnings Report: Can It Continue?

CORAL GABLES, Fla., April  08, 2020  (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today provided an update on certain impacts of COVID-19 on its business operations.

Catalyst Pharmaceuticals Provides Update on Impact of COVID-19 Pandemic on its Business Activities

Catalyst Pharmaceuticals, Inc. Has 'Anti-Virus' Protection

Bicycle Therapeutics Plc - ADR

Amicus Therapeutics

Inovio Pharmaceuticals

Novavax

These five biotech stocks could post life-changing gains for early-bird investors.

5 Absurdly Cheap Biotech Stocks That Could Make You Filthy Rich

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q4 2019 Results - Earnings Call Transcript

Catalyst's (CPRX) earnings lag estimates in the fourth quarter. Revenues match the same.

Catalyst's (CPRX) Q4 Earnings Miss Estimates, Revenues Meet

Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

AbbVie

Agenus

Aphria

Atreca

Bristol-Myers

Crinetics Pharmaceuticals Inc

GW Pharmaceuticals

OrganiGram Holdings Inc.

Pfizer

Arcus Biosciences

Sarepta Therapeutics

The coronavirus induced sell-off has created a number of attractive buying opportunities.

These 14 Stocks Are Stupid Cheap

Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.

Do Options Traders Know Something About Catalyst (CPRX) Stock We Don't?

CORAL GABLES, Fla., Feb.  04, 2020  (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of David Ailinger as Vice President, Business Development, reporting directly to Patrick J. McEnany, Catalyst’s Chairman and CEO. Mr. Ailinger will be responsible for leading the Company’s business development and corporate strategy initiatives, including licensing and partnering discussions.

News for Catalyst Pharmaceuticals Stock (CPRX)